Related Experiment Video
Updated: Aug 17, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
N-methyl-N'-nitro-N-nitrosoguanidine activates cell-cycle arrest through distinct mechanisms activated in a
Dillon I Beardsley1, Wan-Ju Kim, Kevin D Brown
1Department of Biochemistry and Molecular Biology, University of Florida College of Medicine, Gainesville, FL 32611, USA.
Abstract:
S(N)1-alkylating agents, such as the mutagenic and cytotoxic drug N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), robustly activate the DNA damage-responsive G(2) checkpoint. Establishment of this checkpoint is dependent on a functional mismatch repair (MMR) system; however, exposure to high doses of MNNG overrides the requirement for MMR to trigger G(2) arrest. In addition, unlike moderate-dose exposure, in which the G(2) checkpoint is attenuated in ataxia-telangiectasia, mutated (ATM)-deficient cells, high-dose MNNG treatment activates G(2) arrest through an ATM-independent mechanism. We document that this arrest is sensitive to the pharmacological agents caffeine and 7-hydroxystaurosporine (UCN-01) that inhibit the checkpoint kinases ATM/ATM and Rad-3-related (ATR) and Chk1/Chk2, respectively. Furthermore, these agents block inactivation of the cell-cycle regulatory molecules Cdc25C and Cdc2, establishing the downstream mechanism through which high-dose MNNG establishes G(2) arrest. Activation of both Chk2 and Chk1 was independent of ATM and MMR in response to high-dose MNNG, unlike the response to moderate doses of this drug. Chk2 was found to be dispensable for cell-cycle arrest in response to high-dose MNNG treatment; however, ATR deficiency and decreased Chk1 expression forced by RNA interference resulted in diminished checkpoint response. These results indicate that MNNG activates the G(2) checkpoint through different mechanisms activated in a dose-dependent fashion.
Insights
High doses of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) activate the G(2) DNA damage checkpoint independently of mismatch repair (MMR) and ATM. This arrest relies on ATR and Chk1 kinases, revealing dose-dependent MNNG checkpoint activation mechanisms.
Area of Science:
- Molecular Biology
- Cell Cycle Regulation
- DNA Damage Response
Background:
- S(N)1-alkylating agents like N-methyl-N itro-N-nitrosoguanidine (MNNG) are mutagenic and cytotoxic.
- The G(2) checkpoint is crucial for DNA damage response and cell cycle progression.
Purpose of the Study:
- To investigate the dose-dependent mechanisms by which MNNG activates the G(2) checkpoint.
- To elucidate the roles of mismatch repair (MMR), ATM, ATR, and Chk1 in MNNG-induced G(2) arrest.
Main Methods:
- Treatment of cells with varying doses of MNNG.
- Utilizing pharmacological inhibitors (caffeine, UCN-01) of checkpoint kinases.
- Employing RNA interference to assess the function of ATR and Chk1.
- Assessing cell-cycle arrest and inactivation of cell-cycle regulators (Cdc25C, Cdc2).
Main Results:
- High-dose MNNG overrides the MMR-dependence for G(2) arrest.
- High-dose MNNG activates G(2) arrest via an ATM-independent pathway.
- ATR and Chk1, but not Chk2, are essential for high-dose MNNG-induced G(2) arrest.
- MNNG activates the G(2) checkpoint through distinct dose-dependent mechanisms.
Conclusions:
- MNNG's activation of the G(2) DNA damage checkpoint is dose-dependent.
- High-dose MNNG utilizes an ATM-independent, ATR/Chk1-dependent pathway for G(2) arrest.
- Understanding these pathways is critical for cancer therapy and mutagenicity studies.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Positive Regulator Molecules
Positive Regulator Molecules
Negative Regulator Molecules
DNA Damage Can Stall the Cell Cycle

